Prelude Therapeutics Incorporated (PRLD) DCF Valuation

Prelude Therapeutics Incorporated (PRLD) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Prelude Therapeutics Incorporated (PRLD) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Simplify Prelude Therapeutics Incorporated (PRLD) valuation with this customizable DCF Calculator! Featuring real Prelude Therapeutics Incorporated (PRLD) financials and adjustable forecast inputs, you can test scenarios and uncover Prelude Therapeutics Incorporated (PRLD) fair value in minutes.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -27.7 -58.2 -112.8 -122.2 -131.1 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .4 .5 2.2 3.0 1.2 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -28.1 -58.8 -115.1 -125.3 -132.3 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 18.9 218.3 291.2 201.7 232.9 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable 2.0 3.9 7.8 6.8 4.6 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure -.8 -.6 -2.3 -3.0 -3.5 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -28.1 -58.8 -114.1 -116.5 -132.3 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -26.5 -56.9 -110.3 -117.5 -136.8 -4.6 .0 .0 .0 .0
WACC, % 10.49 10.49 10.48 10.43 10.49 10.47 10.47 10.47 10.47 10.47
PV UFCF
SUM PV UFCF -4.1
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -4
Net Debt -8
Equity Value 4
Diluted Shares Outstanding, MM 60
Equity Value Per Share 0.07

What You Will Get

  • Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
  • Real-World Data: Prelude Therapeutics Incorporated’s (PRLD) financial data pre-loaded to accelerate your analysis.
  • Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
  • Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
  • Built for Analysts and Investors: Perfect for assessing projections, validating strategies, and enhancing efficiency.

Key Features

  • Comprehensive PRLD Data: Pre-loaded with Prelude Therapeutics' historical financials and future projections.
  • Customizable Assumptions: Modify growth rates, profit margins, discount rates, tax assumptions, and capital investments.
  • Adaptive Valuation Framework: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on user-defined inputs.
  • Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation results.
  • Intuitive Interface: Designed for ease of use, catering to both experienced professionals and newcomers.

How It Works

  1. Download the Template: Gain immediate access to the Excel-based PRLD DCF Calculator.
  2. Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional parameters.
  3. Instant Calculations: The model automatically recalculates Prelude Therapeutics' intrinsic value.
  4. Test Scenarios: Experiment with various assumptions to assess potential valuation shifts.
  5. Analyze and Decide: Utilize the results to inform your investment or financial analysis decisions.

Why Choose This Calculator for Prelude Therapeutics (PRLD)?

  • Accuracy: Leverages real Prelude Therapeutics financial data for precise calculations.
  • Flexibility: Allows users to easily test and adjust inputs to fit their needs.
  • Time-Saving: Eliminate the complexities of creating a DCF model from the ground up.
  • Professional-Grade: Crafted with the expertise and attention to detail expected at the CFO level.
  • User-Friendly: Intuitive design makes it accessible for users without extensive financial modeling knowledge.

Who Should Use This Product?

  • Investors: Accurately assess Prelude Therapeutics' (PRLD) fair value prior to making investment choices.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Prelude Therapeutics (PRLD).
  • Consultants: Easily customize the template for valuation reports tailored to clients involving Prelude Therapeutics (PRLD).
  • Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms like Prelude Therapeutics (PRLD).
  • Educators: Implement it as a teaching resource to illustrate valuation methodologies relevant to Prelude Therapeutics (PRLD).

What the Template Contains

  • Pre-Filled Data: Includes Prelude Therapeutics Incorporated’s historical financials and projections.
  • Discounted Cash Flow Model: Editable DCF valuation model with automated calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on user-defined inputs.
  • Key Financial Ratios: Assess Prelude Therapeutics’ profitability, efficiency, and leverage.
  • Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
  • Clear Dashboard: Visual representations and tables summarizing key valuation outcomes.

No products were found matching.